Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

2.

Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors.

Vallée A, Guillevin C, Wager M, Delwail V, Guillevin R, Vallée JN.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1423-1431. doi: 10.3174/ajnr.A5725. Epub 2018 Jul 26.

PMID:
30049719
3.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
4.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

5.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

6.

High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.

Bone Marrow Transplant. 2017 Aug;52(8):1113-1119. doi: 10.1038/bmt.2017.23. Epub 2017 Apr 24.

7.

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma.

Galinier A, Delwail V, Puyade M.

Case Rep Oncol. 2017 Jan 27;10(1):127-129. doi: 10.1159/000456002. eCollection 2017 Jan-Apr.

8.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F.

Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

PMID:
28041583
9.

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C.

Neurology. 2017 Jan 3;88(1):101-102. doi: 10.1212/WNL.0000000000003420. Epub 2016 Nov 18. No abstract available.

PMID:
27864520
10.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD.

Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.

PMID:
27345636
11.

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.

Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.

PMID:
26688235
12.

Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma.

Cassou-Mounat T, Delwail V, Cayssials E, Terroir M, Puyade M.

Leuk Lymphoma. 2016;57(3):724-5. doi: 10.3109/10428194.2015.1070152. Epub 2015 Aug 13. No abstract available.

PMID:
26148876
13.

[KHSV/EBV associated germinotropic lymphoproliferative disorder: a rare entity, case report and review of the literature].

Taris M, de Mascarel A, Riols M, Delwail V, Milpied N, Dubus P, Parrens M.

Ann Pathol. 2014 Oct;34(5):373-7. doi: 10.1016/j.annpat.2014.06.013. Epub 2014 Sep 26. Review. French.

PMID:
25439990
14.

A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.

Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, Cumin I, Legouffe E, Solal-Celigny P, Chabin M, Ingrand P, Colombat P, Delwail V.

Am J Hematol. 2014 Nov;89(11):1024-9. doi: 10.1002/ajh.23812. Epub 2014 Aug 27.

15.

Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.

Narquin S, Ingrand P, Azais I, Delwail V, Vialle R, Boucecbi S, Tasu JP.

Diagn Interv Imaging. 2013 Jun;94(6):629-36. doi: 10.1016/j.diii.2013.01.005. Epub 2013 May 15.

16.

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3.

17.

Failure of fluorodeoxyglucose positron emission tomography to detect the high-grade transformation of nodular lymphocyte predominant Hodgkin's lymphoma.

Puyade M, Yacoub M, Tomowiak C, Diviné M, Perdrisot R, Guilhot F, Delwail V.

Acta Haematol. 2013;129(4):229-31. doi: 10.1159/000345261. Epub 2013 Jan 11. No abstract available.

PMID:
23328622
18.

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K.

Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.

19.

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P.

Ann Oncol. 2012 Sep;23(9):2380-5. doi: 10.1093/annonc/mds177. Epub 2012 Jul 10.

PMID:
22782332
20.

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A; 405 Study Investigators.

Blood. 2012 Apr 19;119(16):3698-704. doi: 10.1182/blood-2011-09-378323. Epub 2012 Mar 2.

21.

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS.

Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.

22.

Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.

Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, François S, Berthou C, Gyan E, Milpied N; GOELAMS.

Biol Blood Marrow Transplant. 2011 Jun;17(6):935-40. doi: 10.1016/j.bbmt.2010.11.017. Epub 2010 Nov 23.

23.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R.

Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25.

PMID:
20738307
24.

Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.

Arakelyan N, Jais JP, Delwail V, Brière J, Moles-Moreau MP, Sénécal D, Berthou C, Desablens B, Colonna P, Andrieu JM; GOELAMS Hodgkin Lymphoma Network.

Cancer. 2010 Sep 1;116(17):4054-62. doi: 10.1002/cncr.25295.

25.
26.

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramée JF, Arakelyan N, Thyss A, Moluçon-Chabrot C, Delépine R, Milpied N, Colombat P, Deconinck E; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS).

Blood. 2009 Jan 29;113(5):995-1001. doi: 10.1182/blood-2008-05-160200. Epub 2008 Oct 27.

27.
28.

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T.

Bone Marrow Transplant. 2006 Sep;38(6):417-20.

PMID:
16951691
29.

A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.

Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, Colombat P, Hoang-Xuan K, Martin A.

Blood. 2006 Jan 1;107(1):190-6. Epub 2005 Sep 8.

30.

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.

Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet AS, Traulle C, Bouafia-Sauvy F, Giraud C, Salles G, Guilhot F, Coiffier B.

Cancer. 2005 Oct 1;104(7):1434-41.

31.

Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.

Chamorey E, Gressin R, Peyrade F, Rossi JF, Lepeu G, Foussard C, Harrousseau JL, Fabbro M, Richard B, Delwail V, Maisonneuve H, Vilque JP, Thyss A.

Oncology. 2005;69(1):19-26. Epub 2005 Jul 28.

PMID:
16088231
32.

Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.

Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B; French GOELAMS Group.

Haematologica. 2005 Jun;90(6):802-9.

33.

Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.

Foussard C, Colombat P, Maisonneuve H, Berthou C, Gressin R, Rousselet MC, Rachieru P, Pignon B, Mahé B, Ghandour C, Desablens B, Casassus P, Lamy T, Delwail V, Deconinck E.

Ann Oncol. 2005 Mar;16(3):466-72. Epub 2005 Feb 2.

PMID:
15695500
34.

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, Escoffre-Barbe M, Maisonneuve H, Delwail V, Gressin R, Legouffe E, Vilque JP, Desablens B, Jaubert J, Ramee JF, Jenabian A, Thyss A, Le Pourhiet-Le Mevel A, Travade P, Delepine R, Colombat P; GOELAMS.

Blood. 2005 May 15;105(10):3817-23. Epub 2005 Feb 1.

35.

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.

Feugier P, Labouyrie E, Djeridane M, Jenabian A, Dubruille V, Berthou C, Ghandour C, Desablens B, Chaït Y, Casassus P, Delwail V, Ifrah N, Le Mevel A, Lamy T, Brière J, Colonna P, Andrieu JM.

Blood. 2004 Nov 1;104(9):2675-81. Epub 2004 Jul 1.

36.

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.

N Engl J Med. 2004 Mar 25;350(13):1287-95.

37.

Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.

le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM.

Blood. 2004 Jan 1;103(1):58-66. Epub 2003 Aug 7.

38.

[Treatment of high-grade, disseminated non-Hodgkin's lymphoma in elderly patients].

Paccalin M, Lacotte-Thierry L, Delwail V.

Rev Med Interne. 2002 Jul;23(7):632-7. Review. French.

PMID:
12162217
40.

Ovarian sarcoma and acute myelogenous leukaemia.

Lacotte-Thierry L, Thierry A, Brizard F, Delwail V, Sadoun A, Guilhot F, Brizard A.

Hematol J. 2001;2(6):404-5. No abstract available.

PMID:
11920281
41.

[Primary thyroid lymphoma: report of 8 cases].

Paccalin M, Gouet D, Ribouleau V, Delwail V, Lefort G, Babin P, Kraimps JL, Maréchaud R.

Rev Med Interne. 2001 Oct;22(10):934-8. French.

PMID:
11695316
42.

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.

Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A.

Blood. 2001 Mar 15;97(6):1590-7.

43.

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F, Taillan B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Boué A, Benzohra A, Solal-Céligny P.

Blood. 2001 Jan 1;97(1):101-6.

44.

Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.

Deconinck E, Lamy T, Foussard C, Gaillard F, Delwail V, Colombat P, Casassus P, Lemevel A, Brion A, Milpied N.

Br J Haematol. 2000 Jun;109(4):736-42.

PMID:
10929023
45.

Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia.

Lacotte L, Thierry A, Delwail V, Dreyfus B, Guilhot F.

Acta Haematol. 2000;102(3):160-2.

PMID:
10692682
46.

Primary intracerebral malignant lymphoma: report of 248 cases.

Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, Guy G, Lapierre F.

J Neurosurg. 2000 Feb;92(2):261-6.

PMID:
10659013
47.

Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis.

Sadoun A, Lacotte L, Delwail V, Randriamalala E, Patri S, Babin P, Brizard A, Guilhot F.

Bone Marrow Transplant. 1997 Apr;19(7):741-3.

48.

[Chemotherapy of primary cerebral lymphoma].

Delwail V, Bataille B.

Neurochirurgie. 1997;43(6):380-4. French.

PMID:
9706617
49.

Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.

Foussard C, Desablens B, Sensebe L, François S, Milpied N, Deconinck E, Delwail V, Dugay J, Lamy T, Ghandour C, Le Mevel A, Maisonneuve H, Casassus P, Colombat P.

Ann Oncol. 1997;8 Suppl 1:49-52.

PMID:
9187429
50.

[Hypercalcemia in essential hypereosinophilic syndrome].

Lacotte L, Delwail V, Sadoun A, Dreyfus B, Brizard A, Babin P, Guilhot F.

Ann Med Interne (Paris). 1996;147(8):595-6. French. No abstract available.

PMID:
9137691

Supplemental Content

Loading ...
Support Center